Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

The treatment of chronic myeloid leukemia (CML) has been advanced by the development of small-molecule tyrosine kinase inhibitors (TKIs), which target the fusion protein BCR-ABL1 expressed by the Philadelphia chromosome. Ponatinib is a 3rd generation TKI that binds BCR-ABL1 with high affinity and in...

Full description

Bibliographic Details
Main Authors: Fausto Castagnetti, Fabrizio Pane, Gianantonio Rosti, Giuseppe Saglio, Massimo Breccia
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
chronic myeloid leukemia
dosing regimens
low-dose
ponatinib
risk-benefit profile
treatment algorithm
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.642005/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.642005/full

Similar Items